Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

NCT04951323 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Coronavirus Disease 2019 (Covid19)
Hematopoietic Neoplasms

Interventions

DRUG: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)

Sponsor

University of Liege

Collaborators

[object Object]